Physician profile
Victor Eric Chen
NPI 1912433632
$1,920.12
in general payments reported to CMS, 2019-2025
9 companies · $149 in 2025
The $149 reported for 2025 was less than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $412 · 2021: $172 · 2022: $290 · 2023: $812 · 2024: $84.35 · 2025: $149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,045.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,045.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Elekta, INC. | $707.24 | 2019-2025 | Leksell Gamma Knife Icon, Elekta Medical Linear Accelerator |
| Reflexion Medical, INC. | $452.22 | 2023 | Reflexion Medical Radiotherapy System |
| Novocure INC. | $179.32 | 2019-2025 | Optune Gio, Optune Lua (Novottf-200t) |
| Accuray Incorporated | $172.39 | 2021 | |
| Siemens Medical Solutions USA, INC. | $152.52 | 2022 | |
| Sumitomo Pharma America, INC. | $149.72 | 2023 | Orgovyx |
| Boston Scientific Corporation | $60.18 | 2019 | |
| Myovant Sciences INC. | $26.07 | 2022 | |
| Tactile Systems Technology INC | $20.46 | 2025 | Nimbl, Flexitouch Plus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victor Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.